Simultaneous use of mifepristone and misoprostol for early pregnancy termination

Abstract

Objective: Simultaneous mifepristone 200 mg and vaginal misoprostol 800 μg produces a complete abortion rate of approximately 90% at up to 63 days of gestation. The aim of this study was to determine the effectiveness of concurrent administration of mifepristone 200 mg and vaginal misoprostol 600 μg with respect to early medical abortion. Materials and Methods: A total of 254 women with undesired pregnancies of less than 49 days of gestation were enrolled. All women received oral mifepristone 200 mg and vaginal misoprostol 600 μg concurrently. Follow-up assessment by transvaginal ultrasonography was performed 3 days and 2 weeks after treatment. Results: Efficacy outcome was analyzed for 242 women (95.3%) after excluding 12 individuals lost to follow-up. The complete abortion rate was 92.6%. The mean induction to abortion interval was about 5.8 hours. The mean bleeding duration was about 12.6 days. The women indicated that the side effects were tolerable and 90% of them said that their experience was satisfactory. Conclusion: Concurrent administration of oral mifepristone 200 mg and vaginal misoprostol 600 μg is an efficacious regimen for medical abortion of pregnancies up to 49 days of gestation.

Keywords

• Concurrent medical abortion
• Mifepristone
• Misoprostol